Impact of Gender Differences on Outcomes of Peripheral Artery Disease Intervention (from a Nationwide Sample).


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 02 2021
Historique:
received: 31 08 2020
revised: 29 10 2020
accepted: 02 11 2020
pubmed: 21 11 2020
medline: 16 3 2021
entrez: 20 11 2020
Statut: ppublish

Résumé

We aimed to evaluate the role of gender differences in the outcomes of catheter-based peripheral arterial disease interventions on a national level. We queried the National Inpatient Sample Database and identified all patients who presented with acute or symptomatic long term limb ischemia requiring transcatheter nonsurgical peripheral intervention in the years of 2016 to 2017. The primary outcome was major adverse cardiovascular events (MACE), defined as the composite end point of in-hospital mortality, nonfatal stroke, and acute myocardial infarction. Secondary outcomes were the subject components of the primary end point, vascular complications, major bleeding, acute kidney injury, limb amputation, total cost, and length of stay. A total of 58,165 patients were included. The majority were males (57.2%) and of white race (67.1%). On multivariate analysis, female gender was an independent predictor of MACE with an adjusted odd ratio (a-OR) of 1.36 (95% confidence interval [CI]: 1.12 to 1.65, p = 0.002), mortality (a-OR 1.52; 95% CI: 1.12 to 2.04, p = 0.006), nonfatal stroke (a-OR 2.51; 95% CI: 1.56 to 4.03, p < 0.001), major bleeding (a-OR 1.87; 95% CI: 1.53 to 2.28, p < 0.001), and higher cost with an adjusted mean ratio of 1.03 (95% CI: 1.00 to 1.06, p = 0.033). There was no significant difference in the rates of myocardial infarction, vascular complications, limb amputation, acute kidney injury, and length of stay. In conclusion, females presenting with acute or symptomatic long term limb ischemia requiring transcatheter peripheral intervention have a significantly higher composite risk of MACE.

Identifiants

pubmed: 33217346
pii: S0002-9149(20)31227-3
doi: 10.1016/j.amjcard.2020.11.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-132

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Abdalla Hassan (A)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address: hassan.abdalla@mayo.edu.

Ashraf Abugroun (A)

Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Hussein Daoud (H)

Department of Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, Illinois.

Shafaq Mahmoud (S)

University of Massachusetts Medical School, Worcester, Massachusetts.

Saria Awadalla (S)

Division of Epidemiology & Biostatistics, University of Illinois-Chicago, Chicago, Illinois.

Annabelle Volgman (A)

Division of Cardiology, Rush Medical College, Rush University, Chicago, Illinois.

Alvaro Alonso (A)

University of Massachusetts Medical School, Worcester, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH